Australia's most trusted
source of pharma news
Wednesday, 22 January 2025
Posted 22 January 2025 AM
Novartis has moved to protect a $150 million market from generic competition.
The market came under threat last November after a Federal Court judgment determined that a patent term extension applied to heart drug Entresto should not have been granted.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.